Key result
Maternal serum biomarkers such as PlGF, sFlt-1, and sEng, when used in combination with other clinical predictors, show promise for the early prediction and diagnosis of preeclampsia.
Why the study?
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality with an unknown etiology, creating an urgent need for first-trimester markers for prediction.
Design
Review
Authors
Loading...
May aid early preeclampsia prediction via combined biomarkers and clinical factors; leaves open prospective validation before practice change.
Combinations of maternal serum biomarkers, particularly angiogenic and anti-angiogenic factors, along with clinical risk factors, are necessary for the effective early prediction of preeclampsia.
Gandham et al. (2019) conducted a review in Preeclampsia. Maternal serum biomarkers (e.g., PlGF, sFlt-1, sEng) was evaluated. Maternal serum biomarkers such as PlGF, sFlt-1, and sEng, when used in combination with other clinical predictors, show promise for the early prediction and diagnosis of preeclampsia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: